Hub : Traits :

Medication: Blood pressure

177 significantly associated models · 71 unique genes.

Significant Loci

# chr p0 p1 # assoc genes # joint genes best TWAS P best SNP P cond SNP P % var exp joint genes
1 1 5611729 7460433 3 1 9.8e-09 1.8e-08 2.9e-01 96 DNAJC11
2 1 11060075 12600396 3 1 1.3e-14 3.0e-13 2.4e-02 90 CLCN6
3 1 112312154 113743567 3 2 5.6e-10 3.0e-13 1.5e-07 48 CTTNBP2NL RHOC
4 3 26563909 28211713 2 1 2.5e-14 6.9e-15 5.1e-02 94 SLC4A7
5 3 47681881 49365269 5 1 1.3e-08 9.4e-08 1.0e+00 100 ZNF589
6 4 80407869 82578407 2 2 2.9e-09 1.2e-36 8.9e-26 31 C4orf22 PRDM8
7 4 103020804 104627833 4 1 4.0e-08 5.6e-08 1.0e+00 100 CISD2
8 7 6502367 7988091 1 1 1.6e-07 2.2e-05 3.8e-01 96 C1GALT1
9 10 60026425 60829144 1 1 7.6e-08 2.0e-06 2.9e-01 95 BICC1
10 10 95379543 96818402 1 1 7.8e-08 7.2e-08 1.9e-02 81 NOC3L
11 10 115555541 116053000 1 1 7.5e-08 2.5e-06 6.1e-02 84 ADRB1
12 11 1625363 2161858 1 1 7.4e-09 2.6e-10 8.8e-03 83 LSP1
13 11 46543524 48783497 8 3 2.1e-09 7.2e-11 5.4e-03 82 ACP2 AGBL2 NUP160
14 11 99859184 101559718 2 1 2.0e-17 9.3e-17 1.0e+00 100 ARHGAP42
15 11 110721187 112287801 2 1 4.3e-09 2.7e-09 1.0e+00 100 SIK2
16 12 89286081 90799212 2 2 8.3e-10 1.6e-12 6.6e-06 59 ATP2B1 LOC338758
17 12 111154626 113517494 4 1 3.2e-12 1.4e-18 1.7e-08 59 SH2B3
18 13 114302502 115106996 2 1 1.7e-07 3.7e-07 1.0e+00 100 CDC16
19 15 74042497 75930199 8 1 3.7e-11 5.5e-11 1.0e+00 100 CSK
20 15 80743350 81292020 1 1 7.0e-09 5.5e-10 9.9e-03 83 FAM108C1
21 15 90712555 92135418 2 1 2.1e-21 6.8e-17 9.5e-01 100 FES
22 16 89462678 89961957 1 1 2.1e-07 4.3e-06 8.6e-01 100 CHMP1A
23 17 46258510 47718188 4 2 6.4e-09 3.4e-12 1.0e-05 60 SNF8 ZNF652
24 17 60858059 62259376 2 1 1.9e-10 7.4e-10 1.0e+00 100 ACE
25 20 7419920 9648826 1 2 6.4e-10 3.0e-19 2.2e-07 67 PLCB1
26 20 30083621 31469577 1 1 2.9e-09 1.4e-07 1.1e-05 30 TSPY26P
27 20 57525478 58079512 1 1 2.9e-08 9.5e-13 4.7e-06 59 ZNF831
28 21 44251223 45879403 2 1 2.3e-09 1.0e-08 1.2e-01 92 HSF2BP

Pleiotropic Associations

Trait chisq ratio # genes+ # genes++ % genes++ corr corr P genes
Bipolar Disorder (2018) 1.74 1 0 0.0 0.00 1.0e+00 CSK
Bipolar Disorder or Schizophrenia 2.48 4 1 2.2 -0.25 7.5e-01 CHMP1A CLCN6 CSK FES
Depressed Affect (Nagel 2018) 1.94 2 1 2.2 0.00 1.0e+00 NUP160 SH2B3
Intelligence (Savage-Jansen 2018) 1.06 1 0 0.0 0.00 1.0e+00 ACP2
Neuroticism (Nagel 2018) 1.61 1 1 2.2 0.00 1.0e+00 NUP160
Schizophrenia (2018) 2.41 2 1 2.2 0.00 1.0e+00 FES TSPY26P
Schizophrenia vs Biploar Disorder 1.08 1 0 0.0 0.00 1.0e+00 SNF8
Worry (Nagel 2018) 1.24 1 1 2.2 0.00 1.0e+00 NUP160
Alzheimer’s Disease (including proxy) 1.45 1 1 2.2 0.00 1.0e+00 ACE
Irritable Bowel Disease (IBD) 1.13 1 0 0.0 0.00 1.0e+00 LSP1
Ulcerative Colitis (UC) 1.16 1 0 0.0 0.00 1.0e+00 CISD2
Reaction Time 1.93 1 1 2.2 0.00 1.0e+00 SH2B3
Verbal and Numeric Reasoning (VNR) 1.14 1 0 0.0 0.00 1.0e+00 ACP2
Breast Cancer 3.64 6 2 4.4 0.40 4.3e-01 CSK FES HSF2BP LSP1 SIK2 SLC4A7
Age at First Birth 1.28 1 0 0.0 0.00 1.0e+00 ZNF652
Coronary Artery Disease (CAD) 2.18 1 0 0.0 0.00 1.0e+00 SH2B3
Fasting Glucose 2.60 3 0 0.0 0.00 1.0e+00 ACP2 AGBL2 CISD2
HDL Cholesterol 3.48 3 2 4.4 0.00 1.0e+00 ACP2 ADRB1 AGBL2
LDL Cholesterol 1.47 2 0 0.0 0.00 1.0e+00 CSK SH2B3
Lupus 1.40 1 0 0.0 0.00 1.0e+00 CSK
Neuroticism (2016) 1.67 1 1 2.2 0.00 1.0e+00 NUP160
Primary Biliary Cirrhosis 1.90 2 1 2.2 0.00 1.0e+00 CISD2 SH2B3
Rheumatoid Arthritis 1.12 1 0 0.0 0.00 1.0e+00 SH2B3
Schizophrenia (2014) 2.21 3 1 2.2 0.00 1.0e+00 CHMP1A CISD2 FES
Type 2 Diabetes (T2D) (2012) 1.89 1 0 0.0 0.00 1.0e+00 CISD2
Blood Eosinophil Count 6.51 8 4 8.9 0.70 5.3e-02 AGBL2 CDC16 HSF2BP SH2B3 SIK2 TSPY26P ZNF652 ZNF831
Blood Platelet Count 1.52 8 4 8.9 -0.27 5.1e-01 CSK CTTNBP2NL PLCB1 RHOC SH2B3 SIK2 SLC4A7 SNF8
Blood Red Count 1.97 10 4 8.9 0.49 1.5e-01 BICC1 C4orf22 CHMP1A CLCN6 CSK FES HSF2BP NUP160 SH2B3 ZNF589
Blood White Count 3.51 10 4 8.9 0.76 6.7e-03 ACE ACP2 AGBL2 ARHGAP42 FES NUP160 PLCB1 SH2B3 ZNF589 ZNF652
Heel T-Score 1.85 10 6 13.3 0.02 9.6e-01 ACP2 AGBL2 ARHGAP42 BICC1 CTTNBP2NL DNAJC11 LOC338758 NUP160 RHOC SLC4A7
BMI 1.70 10 4 8.9 0.45 1.9e-01 ACP2 C4orf22 CISD2 CSK DNAJC11 FAM108C1 NUP160 SNF8 TSPY26P ZNF652
Height 1.50 17 14 31.1 -0.54 2.5e-02 ACE ACP2 ADRB1 AGBL2 ARHGAP42 BICC1 CDC16 FES LSP1 NOC3L NUP160 RHOC SH2B3 SLC4A7 SNF8 ZNF652 ZNF831
Waist Hip Ratio (WHR) 0.90 2 0 0.0 0.00 1.0e+00 AGBL2 SIK2
Systolic Blood Pressure 21.78 32 29 64.4 0.94 4.0e-16 ACE ACP2 ADRB1 AGBL2 ARHGAP42 ATP2B1 BICC1 C1GALT1 C4orf22 CDC16 CHMP1A CLCN6 CSK CTTNBP2NL DNAJC11 FAM108C1 FES HSF2BP LOC338758 LSP1 NOC3L NUP160 PLCB1 PRDM8 RHOC SH2B3 SIK2 SLC4A7 SNF8 ZNF589 ZNF652 ZNF831
Smoking Status 1.69 3 0 0.0 0.00 1.0e+00 FAM108C1 FES ZNF652
Allergy or Eczema 2.53 8 2 4.4 -0.28 5.0e-01 CISD2 CLCN6 CSK FES HSF2BP SH2B3 SIK2 ZNF652
Cardiovascular Disease 20.17 34 31 68.9 0.98 1.6e-24 ACE ACP2 ADRB1 AGBL2 ARHGAP42 ATP2B1 BICC1 C1GALT1 C4orf22 CDC16 CHMP1A CISD2 CLCN6 CSK CTTNBP2NL DNAJC11 FAM108C1 FES HSF2BP LOC338758 LSP1 NOC3L NUP160 PLCB1 PRDM8 RHOC SH2B3 SIK2 SLC4A7 SNF8 TSPY26P ZNF589 ZNF652 ZNF831
Hypothyroidism (self reported) 4.15 2 1 2.2 0.00 1.0e+00 SH2B3 ZNF589
Respiratory disease 2.03 3 1 2.2 0.00 1.0e+00 FES SIK2 ZNF652
Type 2 Diabetes (T2D) (2018) 2.07 4 0 0.0 0.99 7.6e-03 ACE C1GALT1 SH2B3 SNF8
Lung FEV1/FVC ratio 2.03 7 7 15.6 -0.23 6.3e-01 ARHGAP42 ATP2B1 C1GALT1 CTTNBP2NL DNAJC11 TSPY26P ZNF652
Lung FVC 1.01 5 0 0.0 -0.53 3.6e-01 C1GALT1 CLCN6 CTTNBP2NL SH2B3 TSPY26P
Neuroticism 1.85 1 1 2.2 0.00 1.0e+00 NUP160
Chronotype (morning person) 1.65 1 0 0.0 0.00 1.0e+00 ACP2
Hair Pigment 3.52 11 8 17.8 0.26 4.4e-01 ACP2 AGBL2 ARHGAP42 ATP2B1 C4orf22 CDC16 CHMP1A FES SH2B3 TSPY26P ZNF831
Tanning 5.45 5 2 4.4 -0.19 7.6e-01 CHMP1A CLCN6 CSK SH2B3 TSPY26P
Hand grip strength (left) 1.05 2 0 0.0 0.00 1.0e+00 FES RHOC
Number of treatments/medications taken 6.58 11 5 11.1 0.95 6.8e-06 ACE ARHGAP42 C1GALT1 CISD2 FAM108C1 FES RHOC SH2B3 TSPY26P ZNF652 ZNF831
Sensitivity / hurt feelings 1.81 3 1 2.2 0.00 1.0e+00 CISD2 FES SNF8
Frequency of depressed mood in last 2 weeks 1.40 1 0 0.0 0.00 1.0e+00 NUP160
Relative age of first facial hair 1.06 1 1 2.2 0.00 1.0e+00 C4orf22
Systolic blood pressure, automated reading 13.94 23 19 42.2 0.97 6.3e-14 ACP2 ADRB1 AGBL2 ARHGAP42 ATP2B1 BICC1 C1GALT1 C4orf22 CDC16 CLCN6 CSK DNAJC11 FAM108C1 FES LOC338758 LSP1 NOC3L NUP160 RHOC SH2B3 SLC4A7 ZNF589 ZNF831
Angina 3.68 3 2 4.4 0.00 1.0e+00 FES TSPY26P ZNF652
Medication: Metformin 1.66 1 0 0.0 0.00 1.0e+00 CISD2
Diabetes (father) 1.58 1 0 0.0 0.00 1.0e+00 SNF8
Impedance of leg (right) 1.84 6 3 6.7 -0.06 9.1e-01 ARHGAP42 FAM108C1 FES NOC3L SIK2 ZNF652
Leg fat-free mass (left) 1.03 5 1 2.2 -0.74 1.5e-01 ARHGAP42 CDC16 FAM108C1 FES SH2B3
Trunk fat percentage 1.87 7 1 2.2 0.48 2.7e-01 ACP2 CDC16 DNAJC11 FAM108C1 NOC3L NUP160 SNF8
Hand grip strength (right) 1.04 1 0 0.0 0.00 1.0e+00 RHOC
Fed-up feelings 2.42 3 1 2.2 0.00 1.0e+00 NUP160 SH2B3 SNF8
Taking other prescription medications 3.15 4 2 4.4 0.99 9.2e-03 CISD2 SH2B3 TSPY26P ZNF652
Age when periods started (menarche) 1.65 2 0 0.0 0.00 1.0e+00 CDC16 FAM108C1
Heel bone mineral density (BMD) T-score, automated (left) 1.69 3 0 0.0 0.00 1.0e+00 ACP2 ARHGAP42 DNAJC11
High blood pressure 21.48 34 30 66.7 0.98 1.4e-25 ACE ACP2 ADRB1 AGBL2 ARHGAP42 ATP2B1 BICC1 C1GALT1 C4orf22 CDC16 CHMP1A CISD2 CLCN6 CSK CTTNBP2NL DNAJC11 FAM108C1 FES HSF2BP LOC338758 LSP1 NOC3L NUP160 PLCB1 PRDM8 RHOC SH2B3 SIK2 SLC4A7 SNF8 TSPY26P ZNF589 ZNF652 ZNF831
Hayfever, allergic rhinitis or eczema 2.58 4 2 4.4 -0.53 4.7e-01 CSK HSF2BP SIK2 ZNF652
Stomach or abdominal pain in last month 1.20 1 0 0.0 0.00 1.0e+00 CHMP1A
Supplements: Glucosamine 1.42 1 0 0.0 0.00 1.0e+00 CSK
Medication: Atenolol 7.95 8 2 4.4 0.99 4.7e-07 ADRB1 ARHGAP42 C1GALT1 C4orf22 CLCN6 FES RHOC SH2B3
Medication: Levothyroxine sodium 3.40 1 1 2.2 0.00 1.0e+00 SH2B3
Sitting height 1.36 8 4 8.9 -0.02 9.5e-01 ADRB1 CDC16 DNAJC11 HSF2BP NUP160 SLC4A7 ZNF652 ZNF831
High blood pressure (mother) 8.90 12 1 2.2 0.98 3.9e-08 ADRB1 ARHGAP42 C4orf22 CHMP1A CLCN6 DNAJC11 FES LSP1 RHOC SLC4A7 SNF8 ZNF831
Body mass index (BMI) 1.47 5 2 4.4 0.70 1.9e-01 ACP2 DNAJC11 FAM108C1 NUP160 SNF8
Impedance of leg (left) 1.88 7 3 6.7 -0.08 8.7e-01 ARHGAP42 FAM108C1 FES NOC3L RHOC SIK2 ZNF652
Leg predicted mass (left) 1.03 5 1 2.2 -0.73 1.6e-01 ARHGAP42 CDC16 FAM108C1 FES SH2B3
Trunk fat mass 1.58 4 1 2.2 0.65 3.5e-01 CDC16 DNAJC11 FAM108C1 SNF8
Waist circumference 1.41 3 1 2.2 0.00 1.0e+00 CSK DNAJC11 FAM108C1
Number of incorrect matches in round 1.66 2 0 0.0 0.00 1.0e+00 FES NUP160
Past tobacco smoking 1.91 2 0 0.0 0.00 1.0e+00 SH2B3 ZNF652
Alcohol usually taken with meals 1.18 1 0 0.0 0.00 1.0e+00 FES
Nervous feelings 1.17 1 0 0.0 0.00 1.0e+00 NUP160
Hearing difficulty/problems with background noise 1.69 1 0 0.0 0.00 1.0e+00 CSK
Hair/balding pattern: Pattern 2 2.34 2 1 2.2 0.00 1.0e+00 C4orf22 PRDM8
Forced vital capacity (FVC) 1.40 3 1 2.2 0.00 1.0e+00 ACP2 CDC16 RHOC
Heel bone mineral density (BMD) T-score, automated (right) 1.50 3 0 0.0 0.00 1.0e+00 ACP2 ARHGAP42 DNAJC11
Heart attack 3.25 4 1 2.2 0.99 1.5e-02 FES SH2B3 ZNF652 ZNF831
Allergy 3.05 5 2 4.4 0.10 8.7e-01 CISD2 CLCN6 FES SIK2 ZNF652
Diabetes (self-reported) 1.96 2 0 0.0 0.00 1.0e+00 ACE C1GALT1
Hayfever/allergic rhinitis (self-reported) 1.60 1 0 0.0 0.00 1.0e+00 HSF2BP
Medication: Ramipril 7.26 7 2 4.4 0.99 4.0e-05 ARHGAP42 CISD2 CSK FES LSP1 NUP160 ZNF652
Medication: Simvastatin 4.71 4 1 2.2 0.97 3.3e-02 ARHGAP42 DNAJC11 FES ZNF831
Illnesses of siblings 5.56 6 1 2.2 -0.99 5.7e-05 ARHGAP42 C1GALT1 CLCN6 FES SH2B3 ZNF589
Neuroticism score 1.78 1 1 2.2 0.00 1.0e+00 NUP160
Weight 1.17 3 2 4.4 0.00 1.0e+00 CDC16 FAM108C1 SH2B3
Impedance of arm (right) 1.68 7 2 4.4 -0.40 3.7e-01 CISD2 FAM108C1 LSP1 NOC3L SH2B3 SLC4A7 ZNF652
Arm fat percentage (right) 1.84 5 2 4.4 0.63 2.5e-01 ACP2 DNAJC11 FAM108C1 NUP160 SNF8
Trunk fat-free mass 1.14 5 1 2.2 -0.60 2.8e-01 ARHGAP42 CDC16 FAM108C1 SH2B3 SLC4A7
Hip circumference 1.38 6 2 4.4 -0.11 8.3e-01 ACP2 CDC16 CLCN6 DNAJC11 FAM108C1 SH2B3
Father's age at death 2.77 4 2 4.4 -0.99 1.3e-02 CSK FES NOC3L SH2B3
Frequency of tiredness / lethargy in last 2 weeks 1.58 2 0 0.0 0.00 1.0e+00 NUP160 SNF8
Hair/balding pattern: Pattern 3 2.69 2 1 2.2 0.00 1.0e+00 C4orf22 PRDM8
Number of live births 1.50 1 0 0.0 0.00 1.0e+00 CISD2
Forced expiratory volume in 1-second (FEV1) 1.63 6 1 2.2 -0.98 4.4e-04 ACP2 ARHGAP42 C1GALT1 CDC16 RHOC TSPY26P
Asthma 2.75 2 2 4.4 0.00 1.0e+00 SIK2 ZNF652
Medication: Ibuprofen (e.g. Nurofen) 1.25 1 0 0.0 0.00 1.0e+00 CSK
Medication: Cholesterol lowering 5.35 8 1 2.2 0.99 1.5e-06 ARHGAP42 C1GALT1 CLCN6 CSK DNAJC11 FES SIK2 ZNF831
Illnesses of mother 5.91 7 1 2.2 -0.99 5.1e-05 ADRB1 ARHGAP42 FES LSP1 NUP160 SNF8 ZNF652
Forced expiratory volume in 1-second (FEV1), Best measure 1.59 6 0 0.0 -0.98 6.3e-04 ACP2 ARHGAP42 C1GALT1 CDC16 RHOC TSPY26P
Pulse wave Arterial Stiffness index 2.17 2 0 0.0 0.00 1.0e+00 CLCN6 FES
Impedance of arm (left) 1.80 8 3 6.7 -0.40 3.3e-01 CISD2 FAM108C1 LSP1 NOC3L SH2B3 SLC4A7 TSPY26P ZNF652
Arm fat mass (right) 1.45 4 2 4.4 0.69 3.1e-01 DNAJC11 FAM108C1 NUP160 SNF8
Trunk predicted mass 1.13 5 1 2.2 -0.61 2.7e-01 ARHGAP42 CDC16 FAM108C1 SH2B3 SLC4A7
Standing height 1.38 12 8 17.8 -0.43 1.6e-01 ACP2 ADRB1 AGBL2 CDC16 LSP1 NUP160 RHOC SH2B3 SLC4A7 SNF8 ZNF652 ZNF831
Breastfed as a baby 1.28 1 0 0.0 0.00 1.0e+00 FES
Tense / 'highly strung' 1.24 1 0 0.0 0.00 1.0e+00 NUP160
Hair/balding pattern: Pattern 4 3.15 3 1 2.2 0.00 1.0e+00 C4orf22 FES PRDM8
Birth weight of first child 3.84 4 3 6.7 -0.99 1.1e-02 CLCN6 CSK FES SH2B3
Peak expiratory flow (PEF) 1.66 1 0 0.0 0.00 1.0e+00 C1GALT1
Ever highly irritable/argumentative for 2 days 1.63 1 0 0.0 0.00 1.0e+00 LSP1
Blood clot in the leg (DVT) 1.22 1 0 0.0 0.00 1.0e+00 SH2B3
Headache pain in last month 1.63 2 0 0.0 0.00 1.0e+00 CISD2 FES
Medication for cholesterol, blood pressure or diabetes 14.81 28 12 26.7 -0.99 2.7e-26 ACE ACP2 ARHGAP42 ATP2B1 C1GALT1 C4orf22 CDC16 CISD2 CLCN6 CSK CTTNBP2NL DNAJC11 FAM108C1 FES HSF2BP LOC338758 NOC3L PLCB1 PRDM8 RHOC SH2B3 SIK2 SLC4A7 SNF8 TSPY26P ZNF589 ZNF652 ZNF831
Gout (self-reported) 1.49 1 0 0.0 0.00 1.0e+00 SH2B3
Hypothyroidism/myxoedema (self-reported) 3.60 1 1 2.2 0.00 1.0e+00 SH2B3
Medication: Amlodipine 10.40 13 6 13.3 0.87 9.4e-05 ACP2 AGBL2 ARHGAP42 ATP2B1 CLCN6 CTTNBP2NL FAM108C1 FES LSP1 NOC3L RHOC SLC4A7 TSPY26P
Medication: Ventolin 100micrograms inhaler 1.67 1 0 0.0 0.00 1.0e+00 ZNF652
Birth weight 2.85 4 4 8.9 -0.63 3.7e-01 ADRB1 FES SH2B3 SIK2
Chronic bronchitis/emphysema (mother) 1.76 1 0 0.0 0.00 1.0e+00 SIK2
High blood pressure (siblings) 8.37 11 2 4.4 0.99 4.1e-10 ADRB1 AGBL2 ARHGAP42 BICC1 C1GALT1 CLCN6 FES HSF2BP LSP1 RHOC SH2B3
Forced vital capacity (FVC), Best measure 1.30 3 2 4.4 0.00 1.0e+00 ACP2 CDC16 RHOC
Body fat percentage 1.88 8 1 2.2 0.32 4.4e-01 ACP2 C4orf22 DNAJC11 FAM108C1 NOC3L NUP160 SLC4A7 SNF8
Leg fat percentage (right) 1.86 6 1 2.2 0.69 1.3e-01 ACP2 CLCN6 DNAJC11 FAM108C1 NOC3L SNF8
Arm fat-free mass (right) 1.13 4 1 2.2 -0.76 2.4e-01 CDC16 FAM108C1 SH2B3 SLC4A7
Exposure to tobacco smoke outside home 1.29 1 0 0.0 0.00 1.0e+00 SH2B3
Comparative body size at age 10 2.10 5 2 4.4 0.66 2.3e-01 ACP2 AGBL2 DNAJC11 ZNF589 ZNF652
Seen a psychiatrist for nerves, anxiety, tension or depression 1.22 1 0 0.0 0.00 1.0e+00 ADRB1
Wheeze or whistling in the chest in last year 1.98 2 0 0.0 0.00 1.0e+00 SIK2 ZNF652
Pulse wave peak to peak time 2.08 1 0 0.0 0.00 1.0e+00 FES
Medication for pain relief, constipation, heartburn 2.61 4 1 2.2 -0.98 2.5e-02 ACE CISD2 FAM108C1 PRDM8
Angina (self-reported) 3.67 3 1 2.2 0.00 1.0e+00 FES TSPY26P ZNF652
Medication: Allopurinol 1.52 1 0 0.0 0.00 1.0e+00 SH2B3
Medication: Seretide 50 evohaler 1.21 1 0 0.0 0.00 1.0e+00 ZNF652
Mean time to correctly identify matches 2.34 2 1 2.2 0.00 1.0e+00 FES SH2B3
Reproduciblity of spirometry measurement using ERS/ATS criteria 0.97 1 0 0.0 0.00 1.0e+00 CDC16
Whole body fat mass 1.54 4 1 2.2 0.70 3.0e-01 CDC16 DNAJC11 FAM108C1 SNF8
Leg fat mass (right) 1.55 3 2 4.4 0.00 1.0e+00 DNAJC11 FAM108C1 SNF8
Arm predicted mass (right) 1.13 4 1 2.2 -0.68 3.2e-01 CDC16 FAM108C1 SH2B3 SLC4A7
Pulse rate, automated reading 1.23 2 0 0.0 0.00 1.0e+00 C4orf22 SIK2
Alcohol intake frequency. 1.13 1 0 0.0 0.00 1.0e+00 SNF8
Comparative height size at age 10 1.31 7 2 4.4 -0.53 2.3e-01 ACP2 AGBL2 C4orf22 CDC16 FAM108C1 FES SH2B3
Suffer from 'nerves' 1.54 1 1 2.2 0.00 1.0e+00 NUP160
Overall health rating 2.55 6 1 2.2 0.99 1.0e-04 C1GALT1 CISD2 SNF8 TSPY26P ZNF652 ZNF831
Chest pain or discomfort 1.69 1 0 0.0 0.00 1.0e+00 C1GALT1
Had major operations 2.51 2 0 0.0 0.00 1.0e+00 BICC1 ZNF652
Medication: Aspirin 5.54 6 1 2.2 0.99 6.0e-05 FES PRDM8 SH2B3 SIK2 SNF8 ZNF589
Hypertension (Self-reported) 21.81 34 30 66.7 0.98 9.1e-26 ACE ACP2 ADRB1 AGBL2 ARHGAP42 ATP2B1 BICC1 C1GALT1 C4orf22 CDC16 CHMP1A CISD2 CLCN6 CSK CTTNBP2NL DNAJC11 FAM108C1 FES HSF2BP LOC338758 LSP1 NOC3L NUP160 PLCB1 PRDM8 RHOC SH2B3 SIK2 SLC4A7 SNF8 TSPY26P ZNF589 ZNF652 ZNF831
Illnesses of father: Heart disease 3.16 3 1 2.2 0.00 1.0e+00 FES SH2B3 SIK2
Smoking status: Previous 1.60 1 0 0.0 0.00 1.0e+00 SH2B3
Forced expiratory volume in 1-second (FEV1), predicted 1.34 1 0 0.0 0.00 1.0e+00 CDC16
Whole body fat-free mass 1.08 5 1 2.2 -0.59 3.0e-01 ARHGAP42 CDC16 FAM108C1 SH2B3 SLC4A7
Leg fat-free mass (right) 1.07 5 2 4.4 -0.74 1.5e-01 ARHGAP42 CDC16 FAM108C1 FES SH2B3
Arm fat percentage (left) 1.77 5 3 6.7 0.65 2.3e-01 ACP2 DNAJC11 FAM108C1 NUP160 SNF8
Average weekly red wine intake 0.97 1 0 0.0 0.00 1.0e+00 CSK
Handedness (chirality/laterality): Left-handed 1.05 1 0 0.0 0.00 1.0e+00 FES
Mood swings 1.84 1 1 2.2 0.00 1.0e+00 NUP160
Loneliness, isolation 1.88 2 1 2.2 0.00 1.0e+00 NUP160 SH2B3
Long-standing illness, disability or infirmity 1.72 1 0 0.0 0.00 1.0e+00 ZNF652
Ever had bowel cancer screening 1.67 1 0 0.0 0.00 1.0e+00 SIK2
Diabetes diagnosed by doctor 2.16 2 0 0.0 0.00 1.0e+00 ACE CISD2
Mouth/teeth dental problems: Mouth ulcers 1.43 1 0 0.0 0.00 1.0e+00 SH2B3
Medication for cholesterol 8.33 15 3 6.7 -0.98 3.1e-11 ACE ADRB1 ARHGAP42 C4orf22 CHMP1A CISD2 CLCN6 FAM108C1 FES LSP1 PLCB1 RHOC SH2B3 TSPY26P ZNF831
Breast cancer (self-reported) 1.77 1 0 0.0 0.00 1.0e+00 SLC4A7
Asthma (self-reported) 2.76 2 2 4.4 0.00 1.0e+00 SIK2 ZNF652
Osteoarthritis (self-reported) 1.55 2 0 0.0 0.00 1.0e+00 CSK SIK2
Medication: Aspirin 5.74 4 1 2.2 1.00 2.0e-04 FES PRDM8 SIK2 SNF8
Illnesses of father: None of the above (group 1) 4.35 3 1 2.2 0.00 1.0e+00 CDC16 FES SH2B3
Forced expiratory volume in 1-second (FEV1), predicted percentage 1.00 1 0 0.0 0.00 1.0e+00 C1GALT1
Whole body water mass 1.08 5 1 2.2 -0.61 2.8e-01 ARHGAP42 CDC16 FAM108C1 SH2B3 SLC4A7
Leg predicted mass (right) 1.07 5 1 2.2 -0.74 1.5e-01 ARHGAP42 CDC16 FAM108C1 FES SH2B3
Arm fat mass (left) 1.36 4 2 4.4 0.70 3.0e-01 DNAJC11 FAM108C1 NUP160 SNF8
Number of self-reported non-cancer illnesses 6.08 6 4 8.9 0.98 5.8e-04 C1GALT1 CISD2 CLCN6 SH2B3 ZNF652 ZNF831
Miserableness 1.83 1 1 2.2 0.00 1.0e+00 NUP160
Guilty feelings 1.70 1 0 0.0 0.00 1.0e+00 NUP160
Ever taken oral contraceptive pill 1.39 1 0 0.0 0.00 1.0e+00 TSPY26P
Eye problems/disorders: Glaucoma 1.55 2 0 0.0 0.00 1.0e+00 ACP2 AGBL2
Medication: Blood pressure 15.44 25 16 35.6 0.98 1.2e-17 ACE ACP2 ADRB1 AGBL2 ARHGAP42 ATP2B1 BICC1 C1GALT1 C4orf22 CHMP1A CISD2 CLCN6 CSK CTTNBP2NL FAM108C1 FES LSP1 PLCB1 RHOC SH2B3 SIK2 SLC4A7 ZNF589 ZNF652 ZNF831
High cholesterol (Self-reported) 2.67 2 0 0.0 0.00 1.0e+00 ARHGAP42 CLCN6
Medication: Bendroflumethiazide 11.91 22 8 17.8 0.97 9.5e-15 ACP2 ADRB1 AGBL2 ARHGAP42 ATP2B1 BICC1 C1GALT1 CHMP1A CLCN6 CSK CTTNBP2NL FAM108C1 FES LOC338758 LSP1 NUP160 PLCB1 RHOC SH2B3 SIK2 SLC4A7 ZNF831
Medication: Lisinopril 8.15 10 0 0.0 0.98 4.8e-07 AGBL2 ARHGAP42 C4orf22 CHMP1A CSK LSP1 SH2B3 SLC4A7 ZNF589 ZNF831
Illnesses of father: High blood pressure 8.67 13 1 2.2 0.98 3.2e-10 ACE ARHGAP42 ATP2B1 BICC1 C4orf22 CDC16 CHMP1A CLCN6 FES LSP1 NUP160 PLCB1 SH2B3
Ever smoked 1.71 3 0 0.0 0.00 1.0e+00 FES SH2B3 ZNF652
Basal metabolic rate 1.05 3 3 6.7 0.00 1.0e+00 CDC16 FAM108C1 SH2B3
Leg fat percentage (left) 1.88 6 1 2.2 0.99 2.3e-04 ACP2 C1GALT1 DNAJC11 FAM108C1 NOC3L SNF8
Arm fat-free mass (left) 1.17 4 1 2.2 -0.82 1.8e-01 CDC16 FAM108C1 SH2B3 SLC4A7
Number of operations (self-reported) 1.95 1 0 0.0 0.00 1.0e+00 PRDM8
Risk taking 1.18 1 0 0.0 0.00 1.0e+00 FES
Age started oral contraceptive pill 1.34 1 0 0.0 0.00 1.0e+00 ZNF652
Diastolic blood pressure, automated reading 13.06 25 18 40.0 0.96 2.8e-14 ACP2 ADRB1 AGBL2 ARHGAP42 ATP2B1 C1GALT1 C4orf22 CDC16 CHMP1A CISD2 CLCN6 CSK FAM108C1 FES LOC338758 LSP1 NOC3L NUP160 RHOC SH2B3 SIK2 SNF8 ZNF589 ZNF652 ZNF831
Vascular/heart problems diagnosed by doctor 21.01 34 29 64.4 -0.98 4.2e-25 ACE ACP2 ADRB1 AGBL2 ARHGAP42 ATP2B1 BICC1 C1GALT1 C4orf22 CDC16 CHMP1A CISD2 CLCN6 CSK CTTNBP2NL DNAJC11 FAM108C1 FES HSF2BP LOC338758 LSP1 NOC3L NUP160 PLCB1 PRDM8 RHOC SH2B3 SIK2 SLC4A7 SNF8 TSPY26P ZNF589 ZNF652 ZNF831
Pain experienced in last month 1.53 2 0 0.0 0.00 1.0e+00 FAM108C1 SH2B3
Heart attack/myocardial infarction (self-reported) 3.22 4 1 2.2 0.98 1.6e-02 FES SH2B3 ZNF652 ZNF831
Heart disease (siblings) 1.98 1 0 0.0 0.00 1.0e+00 FES
Impedance of whole body 1.81 8 3 6.7 -0.49 2.1e-01 ARHGAP42 CISD2 FAM108C1 LSP1 NOC3L SIK2 SLC4A7 ZNF652
Leg fat mass (left) 1.57 3 2 4.4 0.00 1.0e+00 DNAJC11 FAM108C1 SNF8
Arm predicted mass (left) 1.20 4 1 2.2 -0.78 2.2e-01 CDC16 FAM108C1 SH2B3 SLC4A7

Associations by panel

study tissue # hits % hits/tests avg chisq
GTEx Adipose Subcutaneous 4 0.115 1.8
GTEx Adipose Visceral Omentum 3 0.147 1.8
GTEx Adrenal Gland 2 0.137 1.9
GTEx Artery Aorta 6 0.202 1.9
GTEx Artery Coronary 0 0.000 1.8
GTEx Artery Tibial 6 0.160 1.9
GTEx Brain Caudate basal ganglia 1 0.109 1.7
GTEx Brain Cerebellar Hemisphere 0 0.000 1.7
GTEx Brain Cerebellum 2 0.101 1.8
GTEx Brain Cortex 0 0.000 1.8
GTEx Brain Frontal Cortex BA9 1 0.108 1.8
GTEx Brain Hippocampus 1 0.191 1.8
GTEx Brain Hypothalamus 0 0.000 1.6
GTEx Brain Nucleus accumbens basal ganglia 0 0.000 1.7
GTEx Brain Putamen basal ganglia 1 0.160 1.7
GTEx Breast Mammary Tissue 3 0.152 1.8
GTEx Breast Mammary Tissue (Male) 1 0.084 1.8
GTEx Breast Mammary Tissue (Female) 3 0.182 1.9
GTEx Cells EBV-transformed lymphocytes 4 0.281 1.7
GTEx Cells Transformed fibroblasts 9 0.214 1.9
GTEx Colon Sigmoid 2 0.137 1.8
GTEx Colon Transverse 1 0.048 1.8
GTEx Esophagus Gastroesophageal Junction 2 0.138 1.9
GTEx Esophagus Mucosa 4 0.120 1.8
GTEx Esophagus Muscularis 2 0.062 1.8
GTEx Heart Atrial Appendage 0 0.000 1.8
GTEx Heart Left Ventricle 1 0.065 1.8
GTEx Liver 0 0.000 1.6
GTEx Lung 2 0.070 1.9
GTEx Muscle Skeletal 5 0.173 1.9
GTEx Nerve Tibial 1 0.023 1.8
GTEx Ovary 2 0.220 1.9
GTEx Pancreas 2 0.123 1.8
GTEx Pituitary 1 0.090 1.7
GTEx Prostate 0 0.000 1.9
GTEx Skin Not Sun Exposed Suprapubic 3 0.122 1.9
GTEx Skin Sun Exposed Lower leg 2 0.055 1.8
GTEx Small Intestine Terminal Ileum 0 0.000 1.7
GTEx Spleen 1 0.071 1.8
GTEx Stomach 1 0.069 1.9
GTEx Testis 3 0.095 1.8
GTEx Thyroid 4 0.100 1.8
GTEx Uterus 2 0.353 1.8
GTEx Vagina 2 0.315 1.9
GTEx Whole Blood 1 0.050 1.8
METSIM Adipose 4 0.087 1.7
NTR Blood 3 0.125 1.7
ROSMAP Brain Pre-frontal Cortex 4 0.091 1.9
YFS Blood 5 0.108 1.7
CommonMind Brain Pre-frontal Cortex 8 0.149 1.7
The Cancer Genome Atlas Bladder Urothelial Carcinoma 1 0.060 1.6
The Cancer Genome Atlas Breast Invasive Carcinoma 8 0.182 1.7
The Cancer Genome Atlas Cervical Squamous Cell Carcinoma 2 0.182 1.7
The Cancer Genome Atlas Colon Adenocarcinoma 3 0.145 1.8
The Cancer Genome Atlas Esophageal Carcinoma 0 0.000 1.6
The Cancer Genome Atlas Glioblastoma Multiforme 1 0.098 1.7
The Cancer Genome Atlas Head and Neck Squamous Cell Carcinoma 3 0.110 1.7
The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma 6 0.146 1.8
The Cancer Genome Atlas Kidney Renal Papillary Cell Carcinoma 3 0.146 1.7
The Cancer Genome Atlas Brain Lower Grade Glioma 3 0.070 1.7
The Cancer Genome Atlas Liver Hepatocellular Carcinoma 1 0.090 1.7
The Cancer Genome Atlas Lung Adenocarcinoma 4 0.136 1.8
The Cancer Genome Atlas Lung Squamous Cell Carcinoma 3 0.120 1.8
The Cancer Genome Atlas Ovarian Serous Cystadenocarcinoma 3 0.188 1.7
The Cancer Genome Atlas Pancreatic Adenocarcinoma 3 0.181 1.8
The Cancer Genome Atlas Pheochromocytoma and Paraganglioma 2 0.151 1.7
The Cancer Genome Atlas Prostate Adenocarcinoma 5 0.108 1.6
The Cancer Genome Atlas Rectum Adenocarcinoma 1 0.145 1.6
The Cancer Genome Atlas Soft Tissue Sarcoma 0 0.000 1.8
The Cancer Genome Atlas Skin Cutaneous Melanoma 1 0.187 1.8
The Cancer Genome Atlas Stomach Adenocarcinoma 2 0.119 1.8
The Cancer Genome Atlas Testicular Germ Cell Tumors 1 0.078 1.7
The Cancer Genome Atlas Thyroid Carcinoma 6 0.116 1.7
The Cancer Genome Atlas Uterine Corpus Endometrial Carcinoma 0 0.000 1.8